<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    10807619
   </pmid>
   <datecreated>
    <year>
     2000
    </year>
    <month>
     07
    </month>
    <day>
     03
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2000
    </year>
    <month>
     07
    </month>
    <day>
     03
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2009
    </year>
    <month>
     11
    </month>
    <day>
     18
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0959-8138
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       320
      </volume>
      <issue>
       7245
      </issue>
      <pubdate>
       <year>
        2000
       </year>
       <month>
        May
       </month>
       <day>
        13
       </day>
      </pubdate>
     </journalissue>
     <title>
      BMJ (Clinical research ed.)
     </title>
     <isoabbreviation>
      BMJ
     </isoabbreviation>
    </journal>
    <articletitle>
     Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.
    </articletitle>
    <pagination>
     <medlinepgn>
      1297-303
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVES" nlmcategory="OBJECTIVE">
      To determine the effect of long term inhaled corticosteroids on lung function, exacerbations, and health status in patients with moderate to severe chronic obstructive pulmonary disease.
     </abstracttext>
     <abstracttext label="DESIGN" nlmcategory="METHODS">
      Double blind, placebo controlled study.
     </abstracttext>
     <abstracttext label="SETTING" nlmcategory="METHODS">
      Eighteen UK hospitals. Participants: 751 men and women aged between 40 and 75 years with mean forced expiratory volume in one second (FEV(1)) 50% of predicted normal. Interventions: Inhaled fluticasone propionate 500 microgram twice daily from a metered dose inhaler or identical placebo. Main outcome measures: Efficacy measures: rate of decline in FEV(1) after the bronchodilator and in health status, frequency of exacerbations, respiratory withdrawals. Safety measures: morning serum cortisol concentration, incidence of adverse events.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      There was no significant difference in the annual rate of decline in FEV(1 )(P=0.16). Mean FEV(1) after bronchodilator remained significantly higher throughout the study with fluticasone propionate compared with placebo (P&lt;0.001). Median exacerbation rate was reduced by 25% from 1.32 a year on placebo to 0.99 a year on with fluticasone propionate (P=0.026). Health status deteriorated by 3.2 units a year on placebo and 2.0 units a year on fluticasone propionate (P=0.0043). Withdrawals because of respiratory disease not related to malignancy were higher in the placebo group (25% v 19%, P=0.034).
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      Fluticasone propionate 500 microgram twice daily did not affect the rate of decline in FEV(1) but did produce a small increase in FEV(1). Patients on fluticasone propionate had fewer exacerbations and a slower decline in health status. These improvements in clinical outcomes support the use of this treatment in patients with moderate to severe chronic obstructive pulmonary disease.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Respiratory Medicine, Birmingham Heartlands Hospital, Birmingham B9 5SS. burgeps@aol.com
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Burge
      </lastname>
      <forename>
       P S
      </forename>
      <initials>
       PS
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Calverley
      </lastname>
      <forename>
       P M
      </forename>
      <initials>
       PM
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Jones
      </lastname>
      <forename>
       P W
      </forename>
      <initials>
       PW
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Spencer
      </lastname>
      <forename>
       S
      </forename>
      <initials>
       S
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Anderson
      </lastname>
      <forename>
       J A
      </forename>
      <initials>
       JA
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Maslen
      </lastname>
      <forename>
       T K
      </forename>
      <initials>
       TK
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     ENGLAND
    </country>
    <medlineta>
     BMJ
    </medlineta>
    <nlmuniqueid>
     8900488
    </nlmuniqueid>
    <issnlinking>
     0959-535X
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Androstadienes
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Anti-Inflammatory Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      90566-53-3
     </registrynumber>
     <nameofsubstance>
      fluticasone
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="Cites">
     <refsource>
      Thorax. 1999 Jan;54(1):7-14
     </refsource>
     <pmid version="1">
      10343624
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1999 May 29;353(9167):1819-23
     </refsource>
     <pmid version="1">
      10359405
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1418-22
     </refsource>
     <pmid version="1">
      9603117
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1998 Mar 14;351(9105):773-80
     </refsource>
     <pmid version="1">
      9519948
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Allergy Clin Immunol. 1999 Jun;103(6):1062-8
     </refsource>
     <pmid version="1">
      10359887
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      N Engl J Med. 1999 Jun 24;340(25):1948-53
     </refsource>
     <pmid version="1">
      10379018
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Respir Med. 1999 Mar;93(3):161-6
     </refsource>
     <pmid version="1">
      10464871
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Am Rev Respir Dis. 1992 Jun;145(6):1321-7
     </refsource>
     <pmid version="1">
      1595997
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Respir Med. 1991 Sep;85 Suppl B:25-31; discussion 33-7
     </refsource>
     <pmid version="1">
      1759018
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Ann Intern Med. 1991 Feb 1;114(3):216-23
     </refsource>
     <pmid version="1">
      1824614
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Am Rev Respir Dis. 1991 Jun;143(6):1215-23
     </refsource>
     <pmid version="1">
      2048803
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Eur Respir J. 1988 Jan;1(1):22-6
     </refsource>
     <pmid version="1">
      3366234
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Am Rev Respir Dis. 1987 Nov;136(5):1285-98
     </refsource>
     <pmid version="1">
      3674589
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Am J Respir Crit Care Med. 1995 Aug;152(2):538-44
     </refsource>
     <pmid version="1">
      7633704
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      JAMA. 1994 Nov 16;272(19):1497-505
     </refsource>
     <pmid version="1">
      7966841
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Ann Intern Med. 1993 May 15;118(10):770-8
     </refsource>
     <pmid version="1">
      8470851
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Thorax. 1997 Jan;52(1):67-71
     </refsource>
     <pmid version="1">
      9039248
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1997 May 3;349(9061):1269-76
     </refsource>
     <pmid version="1">
      9142060
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1997 May 24;349(9064):1498-504
     </refsource>
     <pmid version="1">
      9167458
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 2000 Nov 25;321(7272):1349
     </refsource>
     <pmid version="1">
      11186442
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 2000 Nov 25;321(7272):1349
     </refsource>
     <pmid version="1">
      11186443
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 2000 Nov 25;321(7272):1349-50
     </refsource>
     <pmid version="1">
      11186444
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Administration, Inhalation
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Algorithms
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Androstadienes
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Anti-Inflammatory Agents
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Forced Expiratory Volume
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Health Status
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Lung Diseases, Obstructive
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Treatment Outcome
     </descriptorname>
    </meshheading>
   </meshheadinglist>
   <otherid source="NLM">
    PMC27372
   </otherid>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2000
     </year>
     <month>
      5
     </month>
     <day>
      12
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2000
     </year>
     <month>
      7
     </month>
     <day>
      8
     </day>
     <hour>
      11
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2000
     </year>
     <month>
      5
     </month>
     <day>
      12
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     10807619
    </articleid>
    <articleid idtype="pmc">
     PMC27372
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

